Sunday 18 October 2026
Export PBLS’s income statement to Excel — free account
Parabilis Medicines, Inc.
PBLS
Insiders bought in the last twelve months.
22.75
2.43
−9.65%
Follow PBLS
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — |
+1 more quarter Free account |
P/S ratio |
0.00 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(218.45) | — | — | — | |
P/B ratio |
0.76 | — | — | — | |
Price to Tangible BV |
0.76 | — | — | — | |
EV/Sales |
0.00 | — | — | — | |
EV/EBITDA |
1.87 | — | — | — | |
EV/Operating CF |
2.73 | — | — | — | |
EV/FCF |
2.71 | — | — | — | |
Quick Ratio |
17.83 | 6.07 | 0.49 | — | |
Current Ratio |
17.91 | 6.12 | 0.52 | — | |
Net Debt/EBITDA |
22.06 | 6.80 | 0.00 | 0.00 | |
Debt/Assets |
0.58% | 2.79% | 18.00% | — | |
Debt/Equity |
0.01 | 0.04 | (0.88) | — | |
Operating CF/Net income |
0.05 | 0.69 | — | 0.69 | |
Capex/Depreciation |
(1.60) | (0.61) | — | (0.02) | |
Interest Coverage |
(242.31) | (162.51) | — | (92.22) | |
Research and Development Expense of Revenue |
26,606.08% | 0.00% | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
7,876.35% | 0.00% | — | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | — | |
Share Based Compensation of Revenue |
2,455.41% | 0.00% | — | 0.00% | |
Graham Net Nets |
1.26 | — | — | — | |
Graham Number |
0.00 | — | — | — | |
Earnings Yield |
(221.63%) | — | — | — | |
Free Cash Flow Yield |
(15.06%) | — | — | — | |
Revenue per Share |
0.01 | 0.00 | — | 0.00 | |
Operating CF per Share |
(0.13) | (24.00) | — | (15.40) | |
Capex per Share |
(0.02) | (0.18) | — | (0.01) | |
Free Cash Flow per Share |
(0.15) | (24.18) | — | (15.41) | |
Cash per Share |
38.77 | 160.51 | 0.00 | 0.00 | |
Shareholders Equity per Share |
36.24 | 119.13 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
36.24 | 119.13 | 0.00 | 0.00 | |
Free Cash Flow |
(4.24) | (49.57) | — | (31.11) | |
Working Capital |
1,062.56 | 277.83 | (27.43) | — | |
Capital Expenditures |
(0.62) | (0.37) | — | (0.02) | |
Net Current Asset Value |
997.87 | 192.12 | (67.99) | — | |
EV/EBIT |
1.84 | — | — | — | |
Capex to Sales |
4.16 | 0.00 | — | 0.00 | |
Price to Operating Income |
0.00 | — | — | — |
Columns are period end dates · fundamentals updated 30 Sep 2026